“67 | LEBRIKIZUMAB FOR PAEDIATRIC PATIENTS AGED ≥6 MONTHS WITH MODERATE-TO-SEVERE AD: PHASE 3 ADORABLE-1 WEEK-16 RESULTS: L. Stingeni1, L. Eichenfield2, J. Ornelas3, V. Prajapati4, C. Yang5, A. Tanaka6, S. Weidinger7, C. Flohr8, E. Swanson9, L. Martin10, S. Daveiga11, R. Gontijo Lima11, H. Elmaraghy11, E. Pierce11, P. Sen11, G. Gallo11, M. Piruzeli11, A. Larkin11, M. Grau12, Y. Mihaylov12, A. Paller13 | 1Dermatology Section, Department of Medicine and Surgery, University of Perugia, Italy; 2Departments of Dermatology and Pediatrics, University of California San Diego School of Medicine, La Jolla, California, USA; 3Department of Dermatology, Integrative Skin Science and Research, Sacramento, California, USA; 4Dermatology Research Institute, Skin Health & Wellness Centre, Probity Medical Research, and University of Calgary, Calgary, Canada; 5Chang Gung University College of Medicine, Taoyuan, Taiwan; 6Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; 7Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Lübeck, Germany; 8Department of Dermatology and Population Health Sciences, King’s College London, UK; 9Ada West Dermatology, St Luke’s Children’s Hospital Idaho, USA; 10School of Clinical Medicine, UNSW Sydney & Dermatology Department, Sydney Children’s Hospital, Sydney, Australia; 11Eli Lilly and Company, Indianapolis, Indiana, USA; 12Almirall R&D, S.A., Barcelona, Spain; 13Dermatology and Infectious Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA” (2026) Dermatology Reports, 18(s1). doi:10.4081/dr.2026.11114.